Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody

Cardiology Division, University of Texas Health Science Center, Houston 77225.

OBJECTIVES. We tested the hypothesis that cyclic alterations in coronary artery blood flow that occurred after coronary angioplasty could be attenuated or abolished by a monoclonal antibody to the platelet surface membrane GP IIb/IIIa receptor. BACKGROUND. Coronary artery cyclic flow variations may occur after coronary angioplasty in experimental animal models and humans. In animal models of coronary thrombosis, cyclic alterations in flow often have preceded thrombotic occlusion or reocclusion. Several agents that inhibit platelet function have been shown to attenuate or eliminate cyclic flow variations in these models. METHODS. We monitored coronary artery flow in 27 patients for 30 min after coronary angioplasty, using 0.018-in. (0.046 cm) coronary guide wires with pulsed wave Doppler ultrasound transducers on the distal tips. Clinical data were collected and quantitative analyses performed on coronary arteriograms made before and after the angioplasty procedures. We compared findings in patients with and without cyclic flow variations detected. RESULTS. There were 20 men and 7 women. Mean age was 58 years, and 63% had unstable angina. They received standard doses of nitrates, aspirin, heparin, calcium channel antagonists and other medications clinically indicated. Nevertheless, we detected cyclic flow variations in five patients (19%). Four of these patients had stable flow restored with intravenous injection of 0.25 mg/kg normal body weight of monoclonal antibody c7E3 Fab to the platelet GP IIb/IIIa receptor. In one patient, stable flow was restored by repeat dilation when an immediate angiogram revealed renarrowing. Patients developing cyclic alterations in flow had longer lesions (18.7 +/- 7.5 mm vs. 13.1 +/- 5.7 mm, p < 0.05) that had responded less well to angioplasty (stenosis postangioplasty 47 +/- 13% vs. 33 +/- 15%, p < 0.05). CONCLUSIONS. Cyclic alterations in coronary artery blood flow may occur in some patients after coronary angioplasty, despite the use of standard antiplatelet, antithrombotic and antivasospastic medications. We found that they could be eliminated by this monoclonal antibody that blocks the final common event of platelet aggregation.

This article has been cited by other articles:

				J. T. Willerson Myocardial Revascularization with Cardiologic Interventional Devices Card. Surg. Adult, January 1, 2003; 2(2003): 561 - 580. [Full Text]

				H. V. Anderson, J. McNatt, F. J. Clubb, M. Herman, J.-P. Maffrand, F. DeClerck, C. Ahn, L. M. Buja, and J. T. Willerson Platelet Inhibition Reduces Cyclic Flow Variations and Neointimal Proliferation in Normal and Hypercholesterolemic-Atherosclerotic Canine Coronary Arteries Circulation, November 6, 2001; 104(19): 2331 - 2337. [Abstract] [Full Text] [PDF]

				D.J Patel, A.H Gomma, C.J Knight, D.A Mulcahy, C.A Wright, H.J Purcell, and K.M Fox Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina?. An observational study of myocardial ischaemia and its relation to coronary anatomy Eur. Heart J., November 1, 2001; 22(21): 1991 - 1996. [Abstract] [PDF]

				S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]

				J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119 (2009): 321S - 336S. [Full Text] [PDF]

				P. Zoldhelyi, P. J. Beck, R. J. Bjercke, J. C. Ober, X. Hu, J. M. McNatt, S. Akhtar, M. Ahmed, F. J. Clubb Jr., Z.-Q. Chen, et al. Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3065 - H3075. [Abstract] [Full Text] [PDF]

				P. Zoldhelyi, J. McNatt, H. S. Shelat, Y. Yamamoto, Z.-Q. Chen, and J. T. Willerson Thromboresistance of Balloon-Injured Porcine Carotid Arteries After Local Gene Transfer of Human Tissue Factor Pathway Inhibitor Circulation, January 25, 2000; 101(3): 289 - 295. [Abstract] [Full Text] [PDF]

				M van den Brand, G.J Laarman, P.G Steg, I De Scheerder, G Heyndrickx, K Beatt, J Kootstra, and M.L Simoons Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial Eur. Heart J., November 1, 1999; 20(21): 1572 - 1578. [Abstract] [PDF]

				T. Nishida, H. Ueno, N. Atsuchi, R. Kawano, Y. Asada, Y. Nakahara, Y.-i. Kamikubo, A. Takeshita, and H. Yasui Adenovirus-Mediated Local Expression of Human Tissue Factor Pathway Inhibitor Eliminates Shear Stress–Induced Recurrent Thrombosis in the Injured Carotid Artery of the Rabbit Circ. Res., June 25, 1999; 84(12): 1446 - 1452. [Abstract] [Full Text] [PDF]

				J. D. Folts, A. I. Schafer, J. Loscalzo, J. T. Willerson, and J. E. Muller A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials J. Am. Coll. Cardiol., February 1, 1999; 33(2): 295 - 303. [Abstract] [Full Text] [PDF]

				C. Bihour, C. Durrieu-Jais, L. Macchi, C. Poujol, P. Coste, P. Besse, P. Nurden, and A. T. Nurden Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 212 - 219. [Abstract] [Full Text] [PDF]

				K.-I. Kawano, Y. Ikeda, K. Kondo, and K. Umemura Increased cerebral infarction by cyclic flow reductions: studies in the guinea pig MCA thrombosis model Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1998; 275(5): R1578 - R1583. [Abstract] [Full Text] [PDF]

				T. Tsunoda, M. Nakamura, T. Wakatsuki, T. Nishida, T. Asahara, H. Anzai, H. Touma, K. Mitsuo, Y. Soumitsu, H. Sakatani, et al. The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct balloon angioplasty J. Am. Coll. Cardiol., August 1, 1998; 32(2): 338 - 344. [Abstract] [Full Text] [PDF]

				H. V. Anderson, R. E. Jordan, and H. F. Weisman Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(4): 256 - 266. [Abstract] [PDF]

				R. R. Makkar, F. Litvack, N. L. Eigler, M. Nakamura, P. A. Ivey, J. S. Forrester, P. K. Shah, R. E. Jordan, and S. Kaul Effects of GP IIb/IIIa Receptor Monoclonal Antibody (7E3), Heparin, and Aspirin in an Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis Circulation, February 18, 1997; 95(4): 1015 - 1021. [Abstract] [Full Text]

				K. Iwakura, H. Ito, S. Takiuchi, Y. Taniyama, Y. Nakatsuchi, S. Negoro, Y. Higashino, A. Okamura, T. Masuyama, M. Hori, et al. Alternation in the Coronary Blood Flow Velocity Pattern in Patients With No Reflow and Reperfused Acute Myocardial Infarction Circulation, September 15, 1996; 94(6): 1269 - 1275. [Abstract] [Full Text]

				P. Zoldhelyi, J. McNatt, X.-M. Xu, D. Loose-Mitchell, R. S. Meidell, F. J. Clubb Jr, L. M. Buja, J. T. Willerson, and K. K. Wu Prevention of Arterial Thrombosis by Adenovirus-Mediated Transfer of Cyclooxygenase Gene Circulation, January 1, 1996; 93(1): 10 - 17. [Abstract] [Full Text]

				B. S. Coller Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy Circulation, November 1, 1995; 92(9): 2373 - 2380. [Full Text]

				J. Lefkovits, E. F. Plow, and E. J. Topol Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine N. Engl. J. Med., June 8, 1995; 332(23): 1553 - 1559. [Full Text] [PDF]

				M. Kubo-Inoue, K. Egashira, M. Usui, M. Takemoto, K. Ohtani, M. Katoh, H. Shimokawa, and A. Takeshita Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1478 - H1484. [Abstract] [Full Text] [PDF]